Low impact
Ionis Pharmaceuticals shares fell 9% after a Phase 3 trial failure erased a year of gains, with ripple effects across the RNA and rare-disease biotech sector.
Finnhub07/11, 02:37 AM
Related assets
Coming up for IONS
Explore next
Latest IONS news
Bloomberg08/03, 04:58 PM
ZeroHedge07/09, 07:13 PM
bloomberg-industries07/09, 01:55 PM